News
Company News: Patients with Risk Factors Benefit from Using COPAL® G+C from Heraeus Medical in Arthroplasty Procedures
– New studies reveal benefits of dual antibiotic-loaded bone cement (COPAL® G+C) to reduce periprosthetic joint infections in risk for infection patients
– 34% reduction of infection risk for primary procedures
– 57% reduction of infection risk for aseptic knee revisions
Patients at risk of infection benefit from bone cement with a combination of antibiotics
COPAL® G+C bone cement containing two antibiotics has long been used for revisions after replacement of hip or knee joints.
Company News: BellaSeno Wins Prestigious German Innovation Award 2021
– Leading-edge Senella® soft tissue technology awarded for excellence in B2B / medical technologies
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has received the German Innovation Award from the German Design Council for its Senella® technology in the category #W2 Excellence in Business to Business – Medical Technologies. BellaSeno has been chosen among about 700 applicants from 30 countries, covering both bluechip as well as innovative start-up companies.
Company News: MerLion Pharmaceuticals Completes Growth Financing Round
– Proceeds will be used to facilitate MerLion`s production and market launch of XtoroTM
MerLion Pharmaceuticals GmbH (MerLion), a biopharmaceutical company focused on research and development of novel antibiotics for the treatment of serious bacterial infections, today announced the successful completion of a growth financing round raised via a private placement to European strategic investors.
The funds raised will primarily be used to finance the production and market launch of MerLion’s US FDA and Health Canada approved drug XtoroTM, an otic suspension containing finafloxacin for treatment of ear infections.
Company News: ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases
– Company forms international consortium with ProteoGenix SAS and Amsterdam UMC
ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that it has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse. The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases. Research will be conducted by a consortium with ProteoGenix SAS (Strasbourg, France) and Amsterdam University Medical Centres (Amsterdam, The Netherlands).